Free tool
FAERS Monitor: Multihance
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021357 or its brand name (Multihance, Gadobenate Dimeglumine). Reports on generic versions are filed under their own applications.
Reports
4,411
Serious
2,714
62% of reports
Hospitalization
778
Death reported
208
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain623
- nausea598
- nephrogenic systemic fibrosis588
- vomiting513
- hypersensitivity437
- urticaria426
- anxiety384
- dyspnoea356
- injury356
- emotional distress337
- pruritus330
- arthralgia293
- burning sensation272
- mobility decreased264
- paraesthesia263
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 154 |
| 2006 | 124 |
| 2007 | 662 |
| 2008 | 54 |
| 2009 | 196 |
| 2010 | 245 |
| 2011 | 295 |
| 2012 | 135 |
| 2013 | 181 |
| 2014 | 249 |
| 2015 | 181 |
| 2016 | 203 |
| 2017 | 225 |
| 2018 | 229 |
| 2019 | 359 |
| 2020 | 344 |
| 2021 | 133 |
| 2022 | 77 |
| 2023 | 82 |
| 2024 | 77 |
| 2025 | 63 |
| 2026 | 143 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,748 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nephrogenic systemic fibrosisSignal | 588 | 1151.4 | 1057.5 | 543,635 |
| injurySignal | 356 | 24.3 | 22.0 | 7,904 |
| burning sensationSignal | 272 | 18.6 | 16.5 | 4,500 |
| mobility decreasedSignal | 264 | 17.6 | 15.6 | 4,111 |
| emotional distressSignal | 337 | 13.3 | 12.0 | 3,835 |
| urticariaSignal | 426 | 12.2 | 11.1 | 4,373 |
| hypersensitivitySignal | 437 | 11.2 | 10.3 | 4,097 |
| paraesthesiaSignal | 263 | 8.0 | 7.1 | 1,609 |
| anxietySignal | 384 | 6.4 | 5.9 | 1,781 |
| vomitingSignal | 513 | 5.2 | 4.8 | 1,777 |
| painSignal | 623 | 4.8 | 4.5 | 1,949 |
| pruritusSignal | 330 | 4.1 | 3.7 | 783 |
| nauseaSignal | 598 | 3.6 | 3.3 | 1,166 |
| arthralgiaSignal | 293 | 3.4 | 3.0 | 493 |
| dyspnoeaSignal | 356 | 3.0 | 2.7 | 485 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.